Nektar Therapeutics
NKTR
$57.13
$2.284.16%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -51.13% | -52.42% | -51.66% | 22.15% | -0.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -51.13% | -52.42% | -51.66% | 22.15% | -0.08% |
| Cost of Revenue | -- | -- | -- | 9.53% | -64.32% |
| Gross Profit | -40.12% | -18.72% | -20.18% | 27.68% | 68.10% |
| SG&A Expenses | -15.23% | -16.76% | 20.83% | -1.07% | -10.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.85% | -21.70% | -2.26% | -1.26% | 1.34% |
| Operating Income | 8.07% | 1.92% | -28.78% | 19.50% | -2.37% |
| Income Before Tax | 4.03% | 20.14% | -37.99% | 116.63% | 19.28% |
| Income Tax Expenses | -466.67% | -508.70% | 248.57% | -793.10% | 114.75% |
| Earnings from Continuing Operations | 4.14% | 20.57% | -38.26% | 117.26% | 19.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.14% | 20.57% | -38.26% | 117.26% | 19.15% |
| EBIT | 8.07% | 1.92% | -28.78% | 19.50% | -2.37% |
| EBITDA | 5.91% | -1.55% | -33.78% | 16.06% | -4.71% |
| EPS Basic | 29.42% | 21.50% | -27.65% | 115.72% | 26.44% |
| Normalized Basic EPS | 29.53% | -4.66% | -30.43% | 14.60% | 2.51% |
| EPS Diluted | 29.42% | 21.50% | -27.65% | 115.43% | 26.44% |
| Normalized Diluted EPS | 29.53% | -4.66% | -30.43% | 16.14% | 2.51% |
| Average Basic Shares Outstanding | 35.82% | 1.19% | 8.31% | 9.79% | 9.90% |
| Average Diluted Shares Outstanding | 35.82% | 1.19% | 8.31% | 11.81% | 9.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |